This expert panel examines the importance of incorporating MRD testing in ALL and the use of blinatumomab in MRD-positive ALL after CR to provide your patients with better outcomes
New data emphasize the importance of MRD testing in patients with ALL
In this commentary, I share my thoughts on the different laboratory techniques available to measure MRD, including flow cytometry, PCR, and NGS-based assays.
Here are my thoughts on the use of blinatumomab to treat patients with B-cell precursor acute lymphoblastic leukemia with measurable residual disease.
In this downloadable slideset from the MRD in ALL video, Elias Jabbour, MD, Joseph D. Khoury, MD, and Aaron C. Logan, MD, PhD, provide expert perspective on incorporating MRD testing in ALL and the use of blinatumomab in MRD-positive ALL after CR to provide your patients with better outcomes.
Download this resource guide to testing for measurable (minimal) residual disease (MRD) in acute lymphoblastic leukemia to help provide optimal care for your patients with ALL.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.